|Report ID : RNR-90759||Category : Biotechnology||Published Date : March, 2017|
|Publisher : Stratistics MRC||Pages : 143||Format : PDF|
INTRODUCTION B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells. The research focus shifted towards BCMA targeted therapies in 2004, when the role of BCMA was first indicated in the progression of multiple myeloma. It is the second most common type (13%) of all hematological malignancies. The disease proves to be fatal due to serious complications associated with it and the frequent events of re-occurrence of illness. The widespread presence of multiple myeloma and other related B-cell malignancies demands confident diagnosis and treatments. Hence, there is an immediate need for effective therapies for proper medical care. Currently, researchers are actively involved in developing three major types of immunotherapies (classified by product class) targeting BCMA; these are chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies and antibody drug conjugates (ADCs). Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. A number of strategic partnerships have also been inked between various stakeholders to advance R&D activities in this domain. Results of preclinical and clinical studies have demonstrated the potential benefits of this class of therapies; the major highlight being their attractive safety profile. As more molecules undergo clinical validation and eventually get commercialized, we believe the overall interest will continue to rise. In fact, our promising outlook is backed by a strong belief that this novel class of therapies is likely to cater to the current unmet need where the existing treatment modalities are not efficient. The upside could be higher; however, it depends on a favorable market environment, reimbursement practices and regulatory regimes.
1. PREFACE 1.1. Chapter Overview 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. The B-Cell Maturation Antigen 3.2.1. Overview 3.2.2. Mechanism of Action 3.3. Drug Classes for BCMA Targeted Therapies 3.3.1. Bispecific Antibodies 3.3.2. Antibody Drug Conjugates 3.3.3. Chimeric Antigen Receptor T-Cells 3.4. BCMA Targeted Therapies and Research Landscape 3.5. Emergence of BCMA as a Therapeutic Target for the Treatment of Multiple Myeloma 3.5.1. Multiple Myeloma: Introduction and Epidemiology 3.5.2. Multiple Myeloma: Current Treatment Landscape 3.5.3. Multiple Myeloma: Emergence of Novel Targets 188.8.131.52. Immunotherapeutic Targets 184.108.40.206. BCMA: A Promising Antigen 3.6. BCMA Related Targets: A Case Study 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. BCMA Targeted Therapies: Development Pipeline 4.3. BCMA Targeted Therapies: Distribution by Phase of Development 4.4. BCMA Targeted Therapies: Distribution by Type of Molecule 4.5. BCMA Targeted Therapies: Distribution by Type of Developer 4.6. BCMA Targeted Therapies: Distribution by Indication 4.7. BCMA Targeted Therapies: Geographical Landscape 4.8. BCMA Targeted Therapies: Developer Landscape 5. DRUG PROFILES: CLINICAL MOLECULES 5.1. Chapter Overview 5.2. bb2121 (bluebird bio, Celgene) 5.2.1. Drug Specifications 5.2.2. Trial Design and Dosage Regimen 5.2.3. Manufacturing Information 5.2.4. Key Preclinical / Clinical Findings 5.2.5. Collaborations 5.3. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania) 5.3.1. Drug Specifications 5.3.2. Trial Design and Dosage Regimen 5.3.3. Manufacturing Information 5.3.4. Key Preclinical / Clinical Findings 5.3.5. Collaborations 5.4. Anti-BCMA CAR-T (National Cancer Institute) 5.4.1. Drug Specifications 5.4.2. Trial Design and Dosage Regimen 5.4.3. Key Preclinical / Clinical Findings 5.5. Anti-BCMA CAR-T (Southwest Hospital, China) 5.5.1. Drug Specifications 5.5.2. Trial Design and Dosage Regimen 5.6. GSK2857916 / J6M0-mcMMAF (GSK, Seattle Genetics) 5.6.1. Drug Specifications 5.6.2. Mechanism of Action 5.6.3. Trial Design and Dosage Regimen 5.6.4. Key Preclinical / Clinical Findings 5.6.5. Collaborations 5.7. AMG 420 / BI 836909 (Amgen, Boehringer Ingelheim) 5.7.1. Drug Specifications 5.7.2. Mechanism of Action 5.7.3. Trial Design and Dosage Regimen 5.7.4. Technology Overview 5.7.5. Key Preclinical / Clinical Findings 5.7.6. Collaborations 5.8. BCMA Targeted Therapies: Clinical Development Analysis 5.8.1. Clinical Development Analysis: Study Goal Comparison 5.8.2. Clinical Development Analysis: Clinical Endpoint Comparison 5.8.3. Clinical Development Analysis: Interim Trial Results Comparison 6. VENTURE CAPITAL INTEREST 6.1. Chapter Overview 6.2. BCMA Targeted Therapies: List of Funding Instances 6.3. Funding Instances: Distribution by Year 6.4. Funding Instances: Distribution by Type of Model 6.5. Leading Players: Distribution by Number of Funding Instances 6.6. Most Active Venture Capital Firms / Investors 7. RECENT COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models / Agreements 7.3. BCMA Targeted Therapies: Recent Collaborations 7.4. Recent Collaborations: Distribution by Year 7.5. Recent Collaborations: Distribution by Type of Model 7.6. Recent Collaborations: Distribution by Type of Molecule 7.7. Recent Collaborations: Most Active Companies 8. MARKET FORECAST 8.1. Chapter Overview 8.2. Scope and Limitation 8.3. Forecast Methodology 8.4. Overall BCMA Targeted Therapeutics Market 8.5. BCMA Targeted Therapeutics Market: Drug Specific Forecasts 8.5.1. bb2121 (bluebird bio, Celgene) 220.127.116.11. Target Patient Population 18.104.22.168. Sales Forecast 8.5.2. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania) 22.214.171.124. Target Patient Population 126.96.36.199. Sales Forecast 8.5.3. Anti-BCMA CAR-T (National Cancer Institute) 188.8.131.52. Target Patient Population 184.108.40.206. Sales Forecast 8.5.4. Anti-BCMA CAR-T (Southwest Hospital, China) 220.127.116.11. Target Patient Population 18.104.22.168. Sales Forecast 8.5.5. GSK2857916 / J6M0-mcMMAF (GSK, Seattle Genetics) 22.214.171.124. Target Patient Population 126.96.36.199. Sales Forecast 8.5.6. AMG 420 / BI836909 (Amgen, Boehringer Ingelheim) 188.8.131.52. Target Patient Population 184.108.40.206. Sales Forecast 9. CONCLUSION 9.1. BCMA has Emerged as a Potential Antigen for the Treatment of Multiple Myeloma 9.2. Led by a Number of Technological Advances, CAR- T Therapies are the Current Flag-Bearer 9.3. Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups / Small Companies Have Emerged 9.4. Growing Partnerships and Venture Capital Support are Indicative of the Future Potential 9.5. Once Approved, BCMA Targeted Therapies are Poised to Achieve an Accelerated Growth 10. APPENDIX 1: TABULATED DATA 11. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS